Retraction Note: Development of novel anti-Kv 11.1 antibody-conjugated PEG–TiO2 nanoparticles for targeting pancreatic ductal adenocarcinoma cells

Angelica Sette; Jolanda Spadavecchia; Jessem Landoulsi; Sandra Casale; Bernard Haye; Olivia Crociani; Annarosa Arcangeli

doi:10.1007/s11051-025-06264-8

journal article·2025-03Open access

Retraction Note: Development of novel anti-Kv 11.1 antibody-conjugated PEG–TiO2 nanoparticles for targeting pancreatic ductal adenocarcinoma cells

Angelica Sette, Jolanda Spadavecchia, Jessem Landoulsi, Sandra Casale, Bernard Haye, Olivia Crociani, Annarosa Arcangeli

Journal of Nanoparticle Research· Volume 27· Issue 3

This record is marked as retracted by the source. Review the publisher’s notice before using its findings.

Publisher page Open full text

Source abstract

Abstract

[This retracts the article DOI: 10.1007/s11051-013-2111-6.].

The source flagged this abstract for review. Check formulas and completeness against the original publication.

Source: europepmc · Quality: needs review · Source record ↗
Source flags: short_text

Research context

Nanomaterials

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (1)

Show source-provided references

1. Sette A, Spadavecchia J, Landoulsi J et al (2022) Correction to: development of novel anti-Kv 11.1 antibody-conjugated PEG–TiO2 nanoparticles for targeting pancreatic ductal adenocarcinoma cells. J Nanopart Res 24:146. https://doi.org/10.1007/s11051-022-05515-210.1007/s11051-022-05515-2 ↗